Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma
- 28 September 2010
- Vol. 59 (12), 1687-1693
- https://doi.org/10.1136/gut.2010.214916
Abstract
Background and aims Golgi protein 73 (GP73) as a potential serum marker for hepatocellular carcinoma (HCC) has not been validated in large cohort studies. Furthermore, its significance in the assessment of tumour recurrence after HCC resection remains unknown. The aim of this study was to determine the value of serum GP73 in the diagnosis of HCC. Methods Serum GP73 and alpha-fetoprotein (AFP) were compared in a total of 4217 human subjects in this multicentre study, including 1690 healthy adults, 337 hepatitis B virus (HBV) carriers, 512 patients with cirrhosis, 789 patients with HCC, 61 patients with other malignant liver lesions, 206 patients with benign liver lesions and 622 patients with 14 different kinds of non-liver cancers. The main outcome measures were the specificity and sensitivity of GP73 in patients at risk for the development of HCC. Results Using 8.5 relative units as a cut-off value, the sensitivity and specificity of serum GP73 for HCC were 74.6% (95% CI 71.5% to 77.6%) and 97.4% (95% CI 96.8 to 98.3%), compared with 58.2% (95% CI 55.2% to 62.1%) and 85.3% (95% CI 83.4% to 88.1%) for AFP (pConclusions GP73 is an accurate serum marker for the detection of HCC and its recurrence after surgery, with higher sensitivity and specificity than AFP. Clinical implementation of serum GP73 measurement as a standard test for HCC is recommended.Keywords
This publication has 22 references indexed in Scilit:
- Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeuticsExpert Review of Gastroenterology & Hepatology, 2009
- Hepatitis B‐related hepatocellular carcinoma: epidemiological characteristics and disease burdenJournal of Viral Hepatitis, 2009
- Hepatocellular Carcinoma – Epidemiological Trends and Risk FactorsDigestive Diseases, 2009
- Researchers look for 'sweet' method to diagnose cancerNature Medicine, 2007
- Endosomal Trafficking and Proprotein Convertase Cleavage of cis Golgi Protein GP73 Produces Marker for Hepatocellular CarcinomaTraffic, 2007
- Liver Cancer Biomarkers Struggling to SucceedJNCI Journal of the National Cancer Institute, 2007
- GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinomaJournal of Hepatology, 2005
- Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humansProceedings of the National Academy of Sciences of the United States of America, 2005
- Prognostic prediction and treatment strategy in hepatocellular carcinomaJournal of Hepatology, 2002
- GP73, a novel Golgi-localized protein upregulated by viral infectionGene, 2000